Cabozantinib shows significant first-line activity for differentiated thyroid cancer

(American Society for Radiation Oncology) Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Thirty-four of 35 patients in the trial experienced a reduction in tumor size following treatment with the targeted kinase inhibitor, and more than half experienced reductions in excess of 30 percent.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news